The online version of this article (doi:10.1186/1476-4598-11-51) contains supplementary material, which is available to authorized users.
Sheng-Dong Huang, Yang Yuan contributed equally to this work.
The authors declare that they have no competing interests.
SDH and ZYZ designed research and analyzed data. YY, HZC, BLL, DJG, CWZ and SGW carried out molecular biology studies. YY and HZC wrote the paper. All authors read and approved the final manuscript.
The enhancer of zeste homolog 2 (EZH2) was found to be overexpressed and associated with tumor metastasis in esophageal squamous cell carcinoma (ESCC). On the other hand, it was reported that miR-26a, miR-98, miR-101, miR-124, miR-138 and miR-214 could inhibit the expression of EZH2 in some tumors. However, the role of miRNAs in the regulation of EZH2 expression in human ESCC has not been documented. The aim of this study was to determine the role of these miRNAs in the regulation of tumor metastasis via EZH2 overexpression in human ESCC.
The expression of these miRNAs and EZH2 mRNA were examined by qPCR and the expression of EZH2 protein was detected by western blot. The role of these miRNAs in migration and invasion was studied in ESCC cell line (Eca109) transfected with miRNA mimics or cotransfected with miRNA mimics and pcDNA-EZH2 plasmid (without the 3’-UTR of EZH2). Through clinical investigation, we found that miR-98 and miR-214 expression was significantly lower in ESCC tissues than in matched normal tissues, and the expression level of miR-98 and miR-214 was inversely correlated to EZH2 protein expression and the clinical features such as pathological grade, tumor stage and lymph node metastasis in ESCC. In Eca109 cells, overexpression of miR-98 and miR-214 significantly inhibited the migration and invasion of ESCC cells, which was reversed by transfection of EZH2.
These findings suggest that decreased expression of miR-98 and miR-214 might promote metastasis of human ESCC by inducing accumulation of EZH2 protein.
Additional file 1: Figure S1.The expression level of EZH2 protein in ESCC and paired normal tissues. (PDF 12 KB)12943_2012_1036_MOESM1_ESM.pdf
Additional file 2: Figure S2.The expression levels of miRNAs were significantly increased in Eca109 cells transfected with miRNA mimics. (PDF 19 KB)12943_2012_1036_MOESM2_ESM.pdf
Additional file 3: Figure S3.The expression levels of EZH2 was significantly increased in Eca109 cells transfected with pcDNA.EZH2. (PDF 18 KB)12943_2012_1036_MOESM3_ESM.pdf
Authors’ original file for figure 112943_2012_1036_MOESM4_ESM.jpeg
Authors’ original file for figure 212943_2012_1036_MOESM5_ESM.jpeg
Authors’ original file for figure 312943_2012_1036_MOESM6_ESM.jpeg
Authors’ original file for figure 412943_2012_1036_MOESM7_ESM.jpeg
Authors’ original file for figure 512943_2012_1036_MOESM8_ESM.jpeg
Authors’ original file for figure 612943_2012_1036_MOESM9_ESM.jpeg
Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J: Vande Woude G, Wong J: Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res. 2005, 11 (17): 6190-6197. 10.1158/1078-0432.CCR-04-2553 CrossRefPubMed
Xie F, Li K, Ouyang X: Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clinical & experimental metastasis. 2009, 26 (8): 1025-1032. 10.1007/s10585-009-9292-5 CrossRef
Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, Lu C, Wang Z, Shi X, Zhang Q, Zhang D, Shen Z, Li F, Harris CC, Cai H, Ke Y: Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. BMC Cancer. 2010, 10: 19- 10.1186/1471-2407-10-19 PubMedCentralCrossRefPubMed
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003, 100 (20): 11606-11611. 10.1073/pnas.1933744100 PubMedCentralCrossRefPubMed
van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM: Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 2007, 52 (2): 455-463. 10.1016/j.eururo.2006.11.020 CrossRefPubMed
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006, 24 (2): 268-273. CrossRefPubMed
Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, Persiani R, Giordano A, Claudio PP: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol. 2007, 210 (1): 183-191. 10.1002/jcp.20833 CrossRefPubMed
Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R: An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol. 2012, 23 (5): 1207-1213. 10.1093/annonc/mdr387 CrossRefPubMed
He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF, Xie D: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010, 127 (1): 138-147. 10.1002/ijc.25031 CrossRefPubMed
Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B, Liu FF: Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell death & disease. 2010, 1: e85- 10.1038/cddis.2010.64 CrossRef
Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V: Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. 2011, 32 (11): 1607-1614. 10.1093/carcin/bgr184 PubMedCentralCrossRefPubMed
Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic cancer. Journal of hematology & oncology. 2010, 3: 46 10.1186/1756-8722-3-46 CrossRef
Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68 (2): 425-433. 10.1158/0008-5472.CAN-07-2488 CrossRefPubMed
Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, Einvik C: Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011, 105 (2): 296-303. 10.1038/bjc.2011.220 PubMedCentralCrossRefPubMed
- MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II